Table II.
Reported clinical evaluations of Akt inhibitors.
| Therapeutic regimen | Indication | Status |
|---|---|---|
| GSK690693 | Hematological neoplasia, acute lymphoblastic leukemia | Clinical development terminated due to hyperglycemia |
| AZD5363 monotherapy | Breast cancer, gastric cancer, prostate cancer | Phase I/phase II clinical trials |
| Afuresertib (GSK2110183) monotherapy | Relapsed or refractory multiple myeloma | Phase I/phase II clinical trials |
| Afuresertib (GSK2110183) in combination with bortezomib or dexamethasone | Relapsed or refractory multiple myeloma | Phase I/Phase II clinical trials |
| Uprosertib (GSK2141795) monotherapy | Relapsed or refractory multiple myeloma | Phase I/phase II clinical trials |
| Uprosertib (GSK2141795) in combination with trametinib | Relapsed or refractory multiple myeloma | Phase I/phase II clinical trials |
| Ipatasertib (GDC-0068, RG7440) monotherapy | Triple-negative breast cancer | Phase I/phase II clinical trials |
| MK-2206 in combination with gefitinib or erlotinib | Advanced non-small-cell lung carcinoma | Phase I/phase II clinical trials |
| MK-2206 monotherapy | Acute myelogenous leukemia | Unsatisfactory clinical results Usage limited to topical application due to hemolytic toxicity after intravenous injection |
| MK-2206 in combination with selumetinib | Colorectal carcinoma | Unsatisfactory clinical results Similar toxicity as for monotherapy |
| MK-2206 monotherapy | Non-cancerous disease (visceral and cutaneous leishmaniasis) | Early clinical evaluation |
| TCN or TCN-P monotherapy | Solid tumors, hematological malignancies | Clinical efficacy limited due to toxicity |